Maternal COVID-19 Vaccine May Reduce the Risk of MIS-C in Infants: A Narrative Review
COVID-19 infection in the pediatric population usually leads to a mild illness; however, a rare but serious complication of MIS-C has been seen in children. MIS-C usually presents 2–4 weeks after COVID-19 infection or exposure, and rare reports have been documented in neonates. Vaccinations for COVI...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/9/1454 |
| _version_ | 1797481601378025472 |
|---|---|
| author | Chetna Mangat Siva Naga Srinivas Yarrarapu Gagandeep Singh Pankaj Bansal |
| author_facet | Chetna Mangat Siva Naga Srinivas Yarrarapu Gagandeep Singh Pankaj Bansal |
| author_sort | Chetna Mangat |
| collection | DOAJ |
| description | COVID-19 infection in the pediatric population usually leads to a mild illness; however, a rare but serious complication of MIS-C has been seen in children. MIS-C usually presents 2–4 weeks after COVID-19 infection or exposure, and rare reports have been documented in neonates. Vaccinations for COVID-19 have been approved for children aged 6 months and above in the United States, and recent reports suggest significantly low prevalence and risk of complications of Multi-organ Inflammatory Syndrome (MIS-C) in vaccinated children compared to unvaccinated children. Vaccinations for COVID-19 are safe and recommended during pregnancy and prevent severe maternal morbidity and adverse birth outcomes. Evidence from other vaccine-preventable diseases suggests that through passive transplacental antibody transfer, maternal vaccinations are protective against infections in infants during the first 6 months of life. Various studies have demonstrated that maternal COVID-19 vaccination is associated with the presence of anti-spike protein antibodies in infants, persisting even at 6 months of age. Further, completion of a 2-dose primary mRNA COVID-19 vaccination series during pregnancy is associated with reduced risk for COVID-19–associated hospitalization among infants aged 6 months or less. Therefore, it can be hypothesized that maternal COVID-19 vaccination can reduce the risk of and severity of MIS-C in infants. In this article, we review the literature to support this hypothesis. |
| first_indexed | 2024-03-09T22:16:56Z |
| format | Article |
| id | doaj.art-1a6f009165eb4dc08addb67236fcdfd9 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T22:16:56Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-1a6f009165eb4dc08addb67236fcdfd92023-11-23T19:21:22ZengMDPI AGVaccines2076-393X2022-09-01109145410.3390/vaccines10091454Maternal COVID-19 Vaccine May Reduce the Risk of MIS-C in Infants: A Narrative ReviewChetna Mangat0Siva Naga Srinivas Yarrarapu1Gagandeep Singh2Pankaj Bansal3Department of Pediatrics, Mayo Clinic Health System, 733 W Clairemont Ave, Eau Claire, WI 54701, USADepartment of Internal Medicine, Monmouth Medical Center/RWJBH, Long Branch, NJ 07740, USADepartment of Family Medicine, Mayo Clinic Health System, 733 W Clairemont Ave, Eau Claire, WI 54701, USADepartment of Rheumatology, Mayo Clinic Health System, 1400 Bellinger Street, Eau Claire, WI 54701, USACOVID-19 infection in the pediatric population usually leads to a mild illness; however, a rare but serious complication of MIS-C has been seen in children. MIS-C usually presents 2–4 weeks after COVID-19 infection or exposure, and rare reports have been documented in neonates. Vaccinations for COVID-19 have been approved for children aged 6 months and above in the United States, and recent reports suggest significantly low prevalence and risk of complications of Multi-organ Inflammatory Syndrome (MIS-C) in vaccinated children compared to unvaccinated children. Vaccinations for COVID-19 are safe and recommended during pregnancy and prevent severe maternal morbidity and adverse birth outcomes. Evidence from other vaccine-preventable diseases suggests that through passive transplacental antibody transfer, maternal vaccinations are protective against infections in infants during the first 6 months of life. Various studies have demonstrated that maternal COVID-19 vaccination is associated with the presence of anti-spike protein antibodies in infants, persisting even at 6 months of age. Further, completion of a 2-dose primary mRNA COVID-19 vaccination series during pregnancy is associated with reduced risk for COVID-19–associated hospitalization among infants aged 6 months or less. Therefore, it can be hypothesized that maternal COVID-19 vaccination can reduce the risk of and severity of MIS-C in infants. In this article, we review the literature to support this hypothesis.https://www.mdpi.com/2076-393X/10/9/1454COVID-19 vaccinepregnancyinfantMIS-C |
| spellingShingle | Chetna Mangat Siva Naga Srinivas Yarrarapu Gagandeep Singh Pankaj Bansal Maternal COVID-19 Vaccine May Reduce the Risk of MIS-C in Infants: A Narrative Review Vaccines COVID-19 vaccine pregnancy infant MIS-C |
| title | Maternal COVID-19 Vaccine May Reduce the Risk of MIS-C in Infants: A Narrative Review |
| title_full | Maternal COVID-19 Vaccine May Reduce the Risk of MIS-C in Infants: A Narrative Review |
| title_fullStr | Maternal COVID-19 Vaccine May Reduce the Risk of MIS-C in Infants: A Narrative Review |
| title_full_unstemmed | Maternal COVID-19 Vaccine May Reduce the Risk of MIS-C in Infants: A Narrative Review |
| title_short | Maternal COVID-19 Vaccine May Reduce the Risk of MIS-C in Infants: A Narrative Review |
| title_sort | maternal covid 19 vaccine may reduce the risk of mis c in infants a narrative review |
| topic | COVID-19 vaccine pregnancy infant MIS-C |
| url | https://www.mdpi.com/2076-393X/10/9/1454 |
| work_keys_str_mv | AT chetnamangat maternalcovid19vaccinemayreducetheriskofmiscininfantsanarrativereview AT sivanagasrinivasyarrarapu maternalcovid19vaccinemayreducetheriskofmiscininfantsanarrativereview AT gagandeepsingh maternalcovid19vaccinemayreducetheriskofmiscininfantsanarrativereview AT pankajbansal maternalcovid19vaccinemayreducetheriskofmiscininfantsanarrativereview |